Welcome to our dedicated page for Acutus Medical SEC filings (Ticker: AFIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Acutus Medical, Inc. (AFIB) SEC filings page on Stock Titan is the place to review the company’s regulatory disclosures in the context of its focused medical device manufacturing business. Acutus reports that it is centered on the production of left-heart access products under a distribution agreement with Medtronic, Inc., and on potential net-sales earnouts under an asset purchase agreement. Its filings with the U.S. Securities and Exchange Commission provide detail on how this business model is reflected in continuing operations, discontinued operations, and the company’s capital structure.
Annual reports (Form 10-K) and quarterly reports (Form 10-Q), where available, typically present separate financial information for continuing operations in left-heart access manufacturing and distribution and for discontinued operations related to the electrophysiology mapping and ablation business. These reports also discuss restructuring activities, workforce reductions, gains on sale of business, and the earnout framework associated with Medtronic’s net end-user sales of left-heart access products.
On Stock Titan, AI-powered tools can help interpret lengthy Acutus filings by highlighting key sections on revenue sources from the Medtronic distribution agreement, the treatment of discontinued operations, and risk factor disclosures. Users can use these insights to better understand topics the company emphasizes in its cautionary language, such as expense management, restructuring execution, acceptance of left-heart access products, dependence on Medtronic, and regulatory considerations.
In addition to periodic reports, investors may consult other SEC documents for information on Acutus’ debt arrangements, equity structure, and any changes related to its trading venue or listing status, as referenced in the company’s forward-looking statements. Stock Titan’s real-time connection to EDGAR and AI summaries are intended to make it easier to navigate these filings and see how Acutus’ focused contract manufacturing model and Medtronic relationship are reflected in its official disclosures.
Acutus Medical, Inc. amendment to a Schedule 13G/A reports updated beneficial ownership disclosures by Advent Life Sciences LLP, Advent Life Sciences Fund I LP and Dr. Shahzad Malik.
The filing states Advent Life Sciences LLP and Advent Life Sciences Fund I LP each hold 0 shares. Dr. Shahzad Malik holds 3,281 restricted shares of common stock and options to purchase 19,476 shares, representing 0.07608% of the class. The reporting persons disclaim beneficial ownership except to the extent of any pecuniary interest. Signatures are dated 02/13/2026.